Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (390)	7/26/2005 9:01:46 AM
From: tom pope	Read Replies (2) \| Respond to of 671

Frankly I was hoping that tuck and or Wilder would come to the rescue on this one. It has the earmarks of one of those wild TASR like rides, but the claim sounds impressive to me - it depends a little on what "up to" means. Three therapeutically relevant doses of 1, 3, or 5 mg/kg resulted in up to a 95% dose dependent reduction in serum HBV DNA levels The phrase "could form the basis for a new class of drugs" may be what's powering the thing. It's up another 10% pre market. The study published in Nature Biotechnology represents the first demonstration that Sirna's technology, which triggers RNA interference, could form the basis of a new class of drugs. RNA interference is a natural, selective process for turning off gene functions. The study suggested a strong scientific foundation for broad human application of RNA interference-based therapeutics. The study showed a 95 percent knockdown of hepatitis B virus with the use of Sirna's chemically optimized short interfering RNA as encapsulated and delivered through technology provided by Protiva Biotherapeutics Inc EDIT - Somewhere I have in the back of my mind that there are people on SI who didn't think too highly of the RZYM people.